December 04, 2019
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs
December 03, 2019
KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs
November 12, 2019
KSQ Therapeutics Enhances Board of Directors with Two Appointments
October 28, 2019
KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine
October 15, 2019
CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology
April 16, 2019
KSQ Therapeutics Announces Appointment of Douglas Pagán as Chief Financial Officer
April 16, 2019
KSQ Therapeutics Announces Appointment of Beni B. Wolf, MD, PhD, as Chief Medical Officer
September 25, 2018
KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors
October 02, 2017
KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development